Close Menu

NEW YORK – Sense Biodetection said Tuesday that it has raised £12.3 million ($15.9 million) to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests.

The Cambridge, UK-based company said it has raised £10.5 million in Series A funding co-led by Cambridge Innovation Capital and Earlybird, with participation from Jonathan Milner and seed round investor Mercia Asset Management. Sense has also secured a grant of £1.8 million from Innovate UK.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.